{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 39,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a table-like structure to present clinical trial milestones and financial runway.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/38",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.115,
        "w": 0.926,
        "x": 0.037,
        "y": 0.746
      },
      "kind": "callout",
      "text": "Cash runway expected to extend into 2025*; Potential Ono Exercise Payment of ~$35M** would significantly extend cash runway",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49db1244-cd29-4b4b-9f77-0d277e7563e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.734,
        "x": 0.163,
        "y": 0.966
      },
      "kind": "source-note",
      "text": "* Estimated based on current operating plan ** Option exercise payment of ¥5.0B is based in JPY and subject to currency exchange rate at the time of payment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3452feba-8f3c-4256-a0a0-73082555217a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.485,
        "w": 0.926,
        "x": 0.037,
        "y": 0.22
      },
      "kind": "table",
      "text": "EQ101 – Phase 2 Clinical Study; Alopecia Areata – Initial Data 2H 2023; Alopecia Areata – Topline Data Mid-2024; EQ102 – Phase 1 Clinical Study; SAD / MAD (healthy volunteers) – Data 2H 2023; Celiac Disease – Data 2024; Itolizumab – Phase 1b / Phase 3 Clinical Studies; Lupus Nephritis EQUALISE Study (Phase 1b) – Topline Data Early 2024; aGVHD EQUATOR Study (Phase 3) – Interim Review 2024",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2c0cd99-0e5c-4d2a-8d88-1fa019081eee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.044,
        "w": 0.178,
        "x": 0.037,
        "y": 0.083
      },
      "kind": "title",
      "text": "Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "918dec12-cd62-48cb-b811-7647070fb505",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "c61e8422-8490-4867-b7e0-91946b97d0b7",
      "evidence": "The slide presents a series of clinical milestones organized by program and expected date.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}